{"id":33821,"date":"2025-05-21T12:55:38","date_gmt":"2025-05-21T04:55:38","guid":{"rendered":"https:\/\/flcube.com\/?p=33821"},"modified":"2025-05-21T12:55:39","modified_gmt":"2025-05-21T04:55:39","slug":"minghui-pharmaceutical-launches-phase-ii-study-of-combination-therapy-for-advanced-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33821","title":{"rendered":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC"},"content":{"rendered":"\n<p>China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.<\/p>\n\n\n\n<p><strong>MHB039A: Bispecific Antibody Innovation<\/strong><br>MHB039A is a novel bispecific antibody (BsAb) targeting PD-1 and VEGF. It has demonstrated robust blocking activities against both PD-1 and VEGF, with superior PD-1 activity compared to competitor antibodies. In a completed Phase I dose-escalation study, MHB039A showed good tolerability at doses up to 30 mg\/kg, with no dose-limiting toxicities (DLTs) observed and the maximum tolerated dose (MTD) not reached. Its safety profile aligns with previously reported PD-1xVEGF bispecific antibodies.<\/p>\n\n\n\n<p><strong>MHB036C: ADC Targeting TROP-2<\/strong><br>MHB036C is a novel antibody-drug conjugate (ADC) targeting TROP-2, developed using Minghui&#8217;s proprietary SuperTopoi ADC platform. In ongoing Phase I\/II studies involving 138 patients with advanced or metastatic solid tumors, MHB036C has demonstrated a favorable safety profile, with no major hematologic adverse events or interstitial lung disease (ILD) reported. Promising anti-tumor activity has been observed, particularly in heavily pre-treated NSCLC and breast cancer patients.<\/p>\n\n\n\n<p><strong>Combination Therapy Potential<\/strong><br>The Phase II study aims to further explore the synergistic potential of combining MHB039A and MHB036C. By leveraging the distinct mechanisms of these two investigational drugs, the study seeks to enhance therapeutic outcomes for patients with advanced NSCLC. This combination approach highlights Minghui Pharmaceutical&#8217;s commitment to innovation in oncology treatment.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33822,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,29,2556,28,18],"class_list":["post-33821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-minghui-pharmaceutical","tag-multi-specific-antibodies","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33821\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC\" \/>\n<meta property=\"og:description\" content=\"China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33821\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T04:55:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T04:55:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC\",\"datePublished\":\"2025-05-21T04:55:38+00:00\",\"dateModified\":\"2025-05-21T04:55:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821\"},\"wordCount\":277,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Minghui Pharmaceutical\",\"Multi-specific antibodies\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33821#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33821\",\"name\":\"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101.webp\",\"datePublished\":\"2025-05-21T04:55:38+00:00\",\"dateModified\":\"2025-05-21T04:55:39+00:00\",\"description\":\"China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33821\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33821#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33821","og_locale":"en_US","og_type":"article","og_title":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC","og_description":"China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.","og_url":"https:\/\/flcube.com\/?p=33821","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-21T04:55:38+00:00","article_modified_time":"2025-05-21T04:55:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33821#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33821"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC","datePublished":"2025-05-21T04:55:38+00:00","dateModified":"2025-05-21T04:55:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33821"},"wordCount":277,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33821#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp","keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","Combination therapy","Minghui Pharmaceutical","Multi-specific antibodies","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33821#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33821","url":"https:\/\/flcube.com\/?p=33821","name":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33821#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33821#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp","datePublished":"2025-05-21T04:55:38+00:00","dateModified":"2025-05-21T04:55:39+00:00","description":"China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of a combination therapy using MHB039A and MHB036C in patients with advanced non-small cell lung cancer (NSCLC). This marks a significant step in the development of novel treatment options for this challenging condition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33821#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33821"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33821#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp","width":1080,"height":608,"caption":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33821#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33821"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33821\/revisions"}],"predecessor-version":[{"id":33823,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33821\/revisions\/33823"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33822"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}